Characterization of two types of intranuclear hepatocellular inclusions in NAFLD.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
06 10 2020
Historique:
received: 22 02 2020
accepted: 26 06 2020
entrez: 7 10 2020
pubmed: 8 10 2020
medline: 5 2 2021
Statut: epublish

Résumé

Nuclear inclusions (NI) are a common finding in hepatocytes from patients with liver disease especially in diabetes mellitus and non-alcoholic fatty liver disease (NAFLD) but studies examining the shape and content of these inclusions in detail are lacking. In this study we define two distinct types of NI in NAFLD: inclusions bounded by the nuclear membrane, containing degenerative cell organelles and heterolysosomes (type1) and inclusions with deposits of glycogen but without any kind of organelles and delimiting membrane (type2). NI in 77 paraffin-embedded patients of NAFLD including NAFL and non-alcoholic steatohepatitis (NASH) were analyzed. In 4-12% of type1 NI immunopositivity for the autophagy-associated proteins LC3B, ubiquitin, p62/sequestosome1, cathepsin D and cathepsin B were detected with co-localizations of ubiquitin and p62; type2 NI showed no immunoreactivity. Three-dimensional reconstructions of isolated nuclei revealed that NI type1 are completely enclosed within the nucleus, suggesting that NI, although probably derived from cytoplasmic invaginations, are not just simple invaginations. Our study demonstrates two morphologically different types of inclusions in NAFLD, whereby both gained significantly in number in advanced stages. We suggest that the presence of autophagy-associated proteins and degenerated organelles within type1 NI plays a role in disease progression.

Identifiants

pubmed: 33024131
doi: 10.1038/s41598-020-71646-y
pii: 10.1038/s41598-020-71646-y
pmc: PMC7538976
doi:

Substances chimiques

MAP1LC3B protein, human 0
Microtubule-Associated Proteins 0
SQSTM1 protein, human 0
Sequestosome-1 Protein 0
Ubiquitin 0
CTSB protein, human EC 3.4.22.1
Cathepsin B EC 3.4.22.1
CTSD protein, human EC 3.4.23.5
Cathepsin D EC 3.4.23.5

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

16533

Références

Bhala, N., Ibrahim Kamal Jouness, R. & Bugianesi, E. Epidemiology and natural history of patients with NAFLD. Curr. Pharm. Des. 19, 5169–5176 (2013).
pubmed: 23394091 doi: 10.2174/13816128113199990336 pmcid: 23394091
Marchesini, G. et al. Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes 50, 1844–1850 (2001).
pubmed: 11473047 doi: 10.2337/diabetes.50.8.1844 pmcid: 11473047
Kälsch, J. et al. Evaluation of biomarkers of NAFLD in a cohort of morbidly obese patients. J. Nutr. Metab. 2011, 369168. https://doi.org/10.1155/2011/369168 (2011).
doi: 10.1155/2011/369168 pubmed: 21773018 pmcid: 3135053
Neuschwander-Tetri, B. A. & Caldwell, S. H. Nonalcoholic steatohepatitis: summary of an AASLD single topic conference. Hepatology 37, 1202–1219 (2003).
pubmed: 12717402 doi: 10.1053/jhep.2003.50193 pmcid: 12717402
Ehrlich, P. Ueber das Vorkommen von Glykogen im diabetischen und im normalen Organismus. Z Klin Med. 6, 33–46 (1883).
Pinto, H. C. et al. Nonalcoholic steatohepatitis. Dig. Dis. Sci. 41, 172–179 (1996).
pubmed: 8565753 doi: 10.1007/BF02208601 pmcid: 8565753
Schulz, H. & Hahnel, E. Ultrastructure of intranuclear glycogen of human hepatocytes in diabetes mellitus. Virchows Arch. B Cell Pathol. 3, 282–294 (1969).
pubmed: 4981179 pmcid: 4981179
Abraham, S. & Furth, E. E. Receiver operating characteristic analysis of glycogenated nuclei in liver biopsy specimens: quantitative evaluation of their relationship with diabetes and obesity. Hum. Pathol. 25, 1063–1068 (1994).
pubmed: 7927311 doi: 10.1016/0046-8177(94)90066-3 pmcid: 7927311
Chipps, H. D. & Duff, G. L. Glycogen infiltration of the liver cell nuclei. Am. J. Pathol. 18, 645–659 (1942).
pubmed: 19970648 pmcid: 2033050
Davies, S. E., Williams, R. & Portmann, B. Hepatic morphology and histochemistry of Wilson’s disease presenting as fulminant hepatic failure: a study of 11 cases. Histopathology 15, 385–394 (1989).
pubmed: 2807195 doi: 10.1111/j.1365-2559.1989.tb01590.x pmcid: 2807195
Levene, A. P. & Goldin, R. D. Physiological hepatic nuclear vacuolation—how long does it persist?. Histopathology 56, 426–429 (2010).
pubmed: 20459549 doi: 10.1111/j.1365-2559.2010.03501.x pmcid: 20459549
Nagore, N. & Scheuer, P. J. The pathology of diabetic hepatitis. J. Pathol. 156, 155–160 (1988).
pubmed: 3199264 doi: 10.1002/path.1711560210 pmcid: 3199264
Sobel, H. J., Schwarz, R. & Marquet, E. Nonviral nuclear inclusions. I. Cytoplasmic invaginations. Arch Pathol. 87, 179–192 (1969).
pubmed: 5763623 pmcid: 5763623
Cowdry, E. V. The microincineration of intranuclear inclusions in yellow fever. Am J Pathol 9, 149–164 (1933).
pubmed: 19970062 pmcid: 2062598
Cowdry, E. V. & Scott, G. H. Nuclear inclusions suggestive of virus action in the salivary glands of the monkey, Cebus fatuellus. Am. J. Pathol. 11, 647–657 (1935).
pubmed: 19970223 pmcid: 1910980
Kleinfeld, R. G. Early changes in rat liver and kidney cells induced by thioacetamide. Cancer Res. 17, 954–962 (1957).
pubmed: 13489694 pmcid: 13489694
Wessel, W. Elektronenmikroskopische Untersuchungen von intranucleaeren Einschlusskoerpern. Virchows Arch. Pathol. Anat. Physiol. Klin Med. 331, 314–328 (1958).
pubmed: 13603980 doi: 10.1007/BF00955258 pmcid: 13603980
Leduc, E. H. & Wilson, J. W. An electron microscope study of intranuclear inclusions in mouse liver and hepatoma. J. Biophys. Biochem. Cytol. 6, 427–430 (1959).
pubmed: 14415166 pmcid: 2224688 doi: 10.1083/jcb.6.3.427
Aravinthan, A. et al. Vacuolation in hepatocyte nuclei is a marker of senescence. J. Clin. Pathol. 65, 557–560 (2012).
pubmed: 22447919 doi: 10.1136/jclinpath-2011-200641 pmcid: 22447919
Schwertheim, S. et al. Intranuclear inclusions in hepatocellular carcinoma contain autophagy-associated proteins and correlate with prolonged survival. J Pathol Clin Res 5, 164–176 (2019).
pubmed: 30859721 pmcid: 6648385 doi: 10.1002/cjp2.129
Schwertheim, S. et al. New insights into intranuclear inclusions in thyroid carcinoma: Association with autophagy and with BRAFV600E mutation. PLoS ONE 14, e0226199 (2019).
pubmed: 31841566 pmcid: 6913918 doi: 10.1371/journal.pone.0226199
Jaskolski, D., Papierz, T., Liberski, P. P. & Sikorska, B. Ultrastructure of meningiomas: autophagy is involved in the pathogenesis of “intranuclear vacuoles”. Folia Neuropathol. 50, 187–193 (2012).
pubmed: 22773465 pmcid: 22773465
Klionsky, D. J. et al. Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy 12, 1–222 (2016).
pubmed: 4835977 pmcid: 4835977 doi: 10.1080/15548627.2015.1100356
Duran, A. et al. The signaling adaptor p62 is an important NF-kappaB mediator in tumorigenesis. Cancer Cell 13, 343–354 (2008).
pubmed: 18394557 doi: 10.1016/j.ccr.2008.02.001 pmcid: 18394557
Yan, X.-Y. et al. p62/SQSTM 1 as an oncotarget mediates cisplatin resistance through activating RIP1-NF-kappaB pathway in human ovarian cancer cells. Cancer Sci. 108, 1405–1413 (2017).
pubmed: 28498503 pmcid: 5497928 doi: 10.1111/cas.13276
Jain, A. et al. p62/SQSTM1 is a target gene for transcription factor NRF2 and creates a positive feedback loop by inducing antioxidant response element-driven gene transcription. J. Biol. Chem. 285, 22576–22591 (2010).
pubmed: 20452972 pmcid: 2903417 doi: 10.1074/jbc.M110.118976
Li, Y. et al. Prevalence of diabetes recorded in mainland China using 2018 diagnostic criteria from the American Diabetes Association: national cross sectional study. BMJ 369, m997 (2020).
pubmed: 32345662 pmcid: 7186854 doi: 10.1136/bmj.m997
Brandts, C. E. Über Einschlüsse im Kern der Leberzelle und ihre Beziehungen zur Pigmentbildung a) beim Hund, b) beim Menschen. Beitr. Pathol. Anat. 45, 457–475 (1909).
Brunt, E. M. & Tiniakos, D. G. Histopathology of nonalcoholic fatty liver disease. World J. Gastroenterol. 16, 5286–5296 (2010).
pubmed: 21072891 pmcid: 2980677 doi: 10.3748/wjg.v16.i42.5286
Levene, A. P. & Goldin, R. D. The epidemiology, pathogenesis and histopathology of fatty liver disease. Histopathology 61, 141–152 (2012).
pubmed: 22372457 doi: 10.1111/j.1365-2559.2011.04145.x pmcid: 22372457
Arora, S. K. & Dey, P. Intranuclear peudoinclusions: morphology, pathogenesis, and significance. Diagn Cytopathol. 40, 741–744 (2012).
pubmed: 21548120 doi: 10.1002/dc.21714 pmcid: 21548120
Ip, Y.-T., Dias Filho, M. A. & Chan, J. K. C. Nuclear inclusions and pseudoinclusions: friends or foes of the surgical pathologist?. Int. J. Surg. Pathol. 18, 465–481 (2010).
pubmed: 21081532 doi: 10.1177/1066896910385342 pmcid: 21081532
Kleinfeld, R. G., Greider, M. H. & Frajola, W. J. Electron microscopy of intranuclear inclusions found in human and rat liver parenchymal cells. J. Biophys. Biochem. Cytol. 2, 435–438 (1956).
pubmed: 13357582 pmcid: 2229668 doi: 10.1083/jcb.2.4.435
Oyama, T. A histopathological, immunohistochemical and ultrastructural study of intranuclear cytoplasmic inclusions in thyroid papillary carcinoma. Virchows Arch. A Pathol. Anat. Histopathol. 414, 91–104 (1989).
pubmed: 2536977 doi: 10.1007/BF00718588 pmcid: 2536977
Tsumuraya, M. et al. Light and electron microscopic analysis of intranuclear inclusions in papillary adenocarcinoma of the lung. Acta Cytol. 25, 523–532 (1981).
pubmed: 6945017 pmcid: 6945017
De Oliveira, S. et al. Metformin modulates innate immune-mediated inflammation and early progression of NAFLD-associated hepatocellular carcinoma in zebrafish. J. Hepatol. 70, 710–721 (2019).
pubmed: 30572006 doi: 10.1016/j.jhep.2018.11.034 pmcid: 30572006
Thakur, P. et al. Dysplastic hepatocytes develop nuclear inclusions in a mouse model of viral hepatitis. PLoS ONE 9, e99872. https://doi.org/10.1371/journal.pone.0099872 (2014).
doi: 10.1371/journal.pone.0099872 pubmed: 24932583 pmcid: 4059674
Ke, P.-Y. Diverse functions of autophagy in liver physiology and liver diseases. Int. J. Mol. Sci. 20, 300. https://doi.org/10.3390/ijms20020300 (2019).
doi: 10.3390/ijms20020300 pmcid: 6358975
Kessler, S. M. et al. IMP2/p62 induces genomic instability and an aggressive hepatocellular carcinoma phenotype. Cell Death Dis. 6, e1894. https://doi.org/10.1038/cddis.2015.241 (2015).
doi: 10.1038/cddis.2015.241 pubmed: 26426686 pmcid: 4632283
Moscat, J. & Diaz-Meco, M. T. p62: a versatile multitasker takes on cancer. Trends Biochem. Sci. 37, 230–236 (2012).
pubmed: 22424619 pmcid: 3531712 doi: 10.1016/j.tibs.2012.02.008
Umemura, A. et al. p62, upregulated during preneoplasia, induces hepatocellular carcinogenesis by maintaining survival of stressed HCC-initiating cells. Cancer Cell 29, 935–948 (2016).
pubmed: 27211490 pmcid: 4907799 doi: 10.1016/j.ccell.2016.04.006
Canbay, A. et al. Cathepsin B inactivation attenuates hepatic injury and fibrosis during cholestasis. J. Clin. Invest. 112, 152–159 (2003).
pubmed: 12865404 pmcid: 164289 doi: 10.1172/JCI200317740
Ikura, Y. Transitions of histopathologic criteria for diagnosis of nonalcoholic fatty liver disease during the last three decades. World J. Hepatol. 6, 894–900 (2014).
pubmed: 25544876 pmcid: 4269908 doi: 10.4254/wjh.v6.i12.894
Kleiner, D. E. et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 41, 1313–1321 (2005).
pubmed: 15915461 pmcid: 15915461 doi: 10.1002/hep.20701
Bedossa, P. & Flip, P. C. Utility and appropriateness of the fatty liver inhibition of progression (FLIP) algorithm and steatosis, activity, and fibrosis (SAF) score in the evaluation of biopsies of nonalcoholic fatty liver disease. Hepatology 60, 565–575 (2005).
doi: 10.1002/hep.27173

Auteurs

Suzan Schwertheim (S)

Institute of Pathology, University Hospital of Essen, University of Duisburg-Essen, Hufelandstr. 55, 45147, Essen, Germany.

Julia Kälsch (J)

Institute of Pathology, University Hospital of Essen, University of Duisburg-Essen, Hufelandstr. 55, 45147, Essen, Germany.
Department of Gastroenterology and Hepatology, University Hospital of Essen, University of Duisburg-Essen, Essen, Germany.

Holger Jastrow (H)

Institute of Anatomy and Electron Microscopy Unit of Imaging Center Essen, University Hospital of Essen, University of Duisburg-Essen, Essen, Germany.

Christoph Matthias Schaefer (CM)

Institute of Pathology, University Hospital of Essen, University of Duisburg-Essen, Hufelandstr. 55, 45147, Essen, Germany.

Sarah Theurer (S)

Institute of Pathology, University Hospital of Essen, University of Duisburg-Essen, Hufelandstr. 55, 45147, Essen, Germany.

Saskia Ting (S)

Institute of Pathology, University Hospital of Essen, University of Duisburg-Essen, Hufelandstr. 55, 45147, Essen, Germany.

Ali Canbay (A)

Department of Medicine, Ruhr University Bochum, University Hospital Knappschaftskrankenhaus Bochum, 44892, Bochum, Germany.

Heiner Wedemeyer (H)

Department of Gastroenterology and Hepatology, University Hospital of Essen, University of Duisburg-Essen, Essen, Germany.

Kurt Werner Schmid (KW)

Institute of Pathology, University Hospital of Essen, University of Duisburg-Essen, Hufelandstr. 55, 45147, Essen, Germany.
West German Cancer Centre Essen (WTZE), Essen, Germany.

Hideo Andreas Baba (HA)

Institute of Pathology, University Hospital of Essen, University of Duisburg-Essen, Hufelandstr. 55, 45147, Essen, Germany. hideo.baba@uk-essen.de.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH